Safety and Efficacy of Empagliflozin in Hemodialysis
Status:
Not yet recruiting
Trial end date:
2025-12-30
Target enrollment:
Participant gender:
Summary
A 12-week, phase II, randomized, double-blind, placebo-controlled, multi-center study to
assess the safety, tolerability, and preliminary efficacy of empagliflozin versus placebo
among patients initiating hemodialysis (n=60) for the treatment of end-stage kidney disease.
Phase:
Phase 2
Details
Lead Sponsor:
NYU Langone Health
Collaborators:
Boehringer Ingelheim National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)